Vectus Biosystems (ASX:VBS) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VBS Vectus Biosystems Ltd ASX:VBS
15 GF Score
Price A$0.18
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems Net Margin %?

Vectus Biosystems ASX:VBS -12.50% 15 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Vectus Biosystems ranks worse than 106269.82% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Vectus Biosystems's Net Income for the six months ended in Dec. 2025 was A$-0.73 Mil. Vectus Biosystems's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Vectus Biosystems's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Vectus Biosystems's Net Margin % or its related term are showing as below:


ASX:VBS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Vectus Biosystems  (ASX:VBS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Vectus Biosystems Net Margin % Related Terms

Vectus Biosystems Net Margin % Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems Net Margin % Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117,800.00 0.00 0.00 0.00 0.00

ASX:VBS vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Vectus Biosystems's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vectus Biosystems Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Net Margin % falls into.


ASX:VBS
15GF Score
Vectus Biosystems Ltd ASX:VBS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vectus Biosystems's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-1.777/0
= %

Vectus Biosystems's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.732/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Vectus Biosystems (ASX:VBS) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Vectus Biosystems and its competitors. According to the industry distribution chart, Vectus Biosystems ranks #999999 out of 941 companies in the Biotechnology industry.
Is Vectus Biosystems' Net Margin % too high?
Vectus Biosystems' current Net Margin % is 0.00%. Based on the distribution chart, Vectus Biosystems ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #999999 out of 941 companies for Net Margin %. This places Vectus Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vectus Biosystems and its competitors. Vectus Biosystems's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score

Get the complete analysis for ASX:VBS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price